Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cybin ( (TSE:CYBN) ) has issued an update.
On September 17, 2025, Cybin Inc. filed a Form 6-K with the United States Securities and Exchange Commission, incorporating Exhibit 99.1 into its Registration Statement on Form F-10. The filing includes consent from Aird & Berlis LLP to reference their firm under specific headings in the Prospectus Supplements, which are part of the registration statement. This step is part of Cybin’s ongoing efforts to strengthen its regulatory compliance and enhance its market presence in the United States.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. operates in the biotechnology industry, focusing on developing psychedelic-based therapies and products for mental health treatment. The company is headquartered in Toronto, Ontario, and is involved in research and development to advance innovative solutions in the mental health sector.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Learn more about CYBN stock on TipRanks’ Stock Analysis page.